New in the NCCN guidelines is lurbinectedin [Zepzelca] and atezolizumab [Tecentriq] maintenance. 2 There are other ...

Rezetapopt showed a 44.4% response rate and durable responses over 8 months in ovarian cancer with p53 Y220C mutation, with ...

U.S. biomonitoring data show that older adults with moderate blood levels of perfluorodecanoic acid (PFDA), a PFAS chemical, have significantly higher odds of developing nonmelanoma skin cancer. The ...

Roswell Park researchers present a two-step, mechanism-based drug strategy at AACR 2026 that selectively targets cancers with ...

The Board leadership transition comes at a pivotal time for PMV Pharma as enrollment continues in the ongoing PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical ...

A recent study examines the association between COVID-19 infection and an increased risk of recurrence in breast cancer ...

Researchers have identified a molecular mechanism that helps prevent common skin cancers from becoming aggressive and metastatic. The study, published in Proceedings of the National Academy of ...

Two inhibitors of the same immune checkpoint family produced high response rates and evidence of durability in preliminary ...

A new study has identified a molecular guardian that keeps skin cells from forgetting what they are and transforming into ...

As we age, our cells accumulate genetic changes—mutations—some of which open the door to cancer. Scientists call these ...

At SGO 2026, Alison Schram, MD, highlighted first-in-class tumor suppressor reactivation and emphasized early NGS testing in ...